VENCLEXTA Abbvie Pty Ltd
Product name
VENCLEXTA
Sponsor
Accepted date
Jul-2024
Active ingredients
venetoclax
Proposed indication
Treatment of chronic lympocytic leukaemia/small lymphocytic lymphoma.
Application type
C (new indication)
Publication date
Jul-2024